Human Activin RIIB / ACVR2B Protein, His Tag (MALS & SPR verified)
分子別名(Synonym)
ACVR2B,ACTRIIB,MGC116908
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Activin RIIB, His Tag (ACB-H5226) is expressed from human 293 cells (HEK293). It contains AA Ser 19 - Thr 137 (Accession # Q13705-1).
Predicted N-terminus: Ser 19
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 14.5 kDa. The protein migrates as 20-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
激活素受體2B型(ACVR2B)也稱為ActR IIB和MGC116908,ACVR2B是激活素2型受體。激活素是二聚體生長和分化因子,屬于結(jié)構(gòu)相關(guān)信號蛋白的轉(zhuǎn)化生長因子-β(TGF-β)超家族。激活素通過受體絲氨酸激酶的異質(zhì)復(fù)合物發(fā)出信號,所述受體絲氨酸激酶包括至少兩種I型(I和IB)和兩種II型(II和IIB)受體。這些受體都是跨膜蛋白,由具有半胱氨酸富集區(qū)的配體結(jié)合胞外結(jié)構(gòu)域、跨膜結(jié)構(gòu)域和具有預(yù)測絲氨酸/蘇氨酸特異性的細(xì)胞質(zhì)結(jié)構(gòu)域組成。I型受體對信號傳導(dǎo)至關(guān)重要;并且II型受體是結(jié)合配體和表達(dá)I型受體所必需的。I型和II型受體在配體結(jié)合后形成穩(wěn)定的復(fù)合物,導(dǎo)致I型受體被II型受體磷酸化。II型受體被認(rèn)為是組成型活性激酶。該基因編碼激活素A IIB型受體,其對配體的親和力是激活素II型受體的3-4倍。ACVR2B缺陷是常染色體4型內(nèi)臟異軸畸形(HTX4)的病因。
關(guān)鍵字: ACVR2B;ACVR2B蛋白;ACTRIIB重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。